ArticleJournal of racial and ethnic health disparities2026
Survival Differences of Localized Papillary Renal Cell Carcinoma in African Americans vs. European Americans.
Article in Journal of racial and ethnic health disparities, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic impact of adjacent organ invasion on cancer-specific mortality in non-metastatic renal cell carcinoma.World journal of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAfrican Americans exhibit a higher prevalence of papillary renal cell carcinoma (pRCC). We assessed overall and cause-specific survival differences between African Americans and European Americans with surgically treated localized pRCC.
methodsAfrican Americans and European Americans who underwent nephrectomy for T1b-2 N0 M0 pRCC were identified within the Surveillance, Epidemiology and End Results database (2004-2021). Propensity score matching (PSM) was applied, and multivariable Cox regression as well as competing-risks regression (CRR) models were fitted.
resultsOf 3,707 patients, 1,345 (36.3%) were African Americans and 2,362 (63.7%) were European Americans. After PSM, no significant differences in socioeconomic, demographic, or tumor-specific characteristics remained between the two groups. Overall survival (OS) rates at 120 months after nephrectomy were 59.4% in African Americans vs. 66.9% in European Americans (p = 0.026). In multivariable Cox regression models, the African American group was associated with higher overall mortality (hazard ratio [HR] 1.24, 95% confidence interval [CI]: 1.05-1.47, p = 0.013). Other-cause mortality (OCM) at 120 months after nephrectomy was higher in African Americans (29.0% vs. 22.2%), while cancer-specific mortality (CSM) did not differ (11.0% vs. 10.3%) between the two populations. Finally, in multivariable CRR models, the African American group predicted higher OCM (HR 1.33, 95% CI: 1.08-1.64, p = 0.007), but did not affect CSM (HR 1.06, 95% CI: 0.77-1.45, p = 0.7).
conclusionIn surgically treated localized pRCC, OS in African American patients is lower compared to European American patients. This difference in OS is not explained by CSM. Instead, it reflects significantly higher OCM in African American patients.
Indexed as
Identifiers
42288708What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.